Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Bruce E. Sands; Geert DʼHaens; David B. Clemow; Peter M. Irving; Jordan Johns; Theresa Hunter; María T. Abreu; Scott D. Lee; Tadakazu Hisamatsu; Taku Kobayashi; Marla C. Dubinsky; Séverine Vermeire; Corey A. Siegel; Laurent Peyrin‐Biroulet; Richard Moses; Joe Milata; Vipin Arora; Remo Panaccione; Axel Dignaß

doi:10.1093/ibd/izae024

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in patients with moderately to severely active ulcerative colitis. Results are presented from the open-label extension study through W104.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sands et al. (2024) studied this question.

synapsesocial.com/papers/68e74cd0b6db6435876c5522 https://doi.org/10.1093/ibd/izae024

View Full Paper

Ask AI

Bookmark

Share

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Ask about this paper

Abstract

Discussion

Cite This Study

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading